Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV

被引：7

作者：

Kreutzwiser, Denise ^{[1
,2
,3
]}

Sheehan, Nancy ^{[1
,4
,5
]}

Dayneka, Natalie ^{[6
]}

Lemire, Benoit ^{[1
,4
]}

Wong, Alison ^{[1
,4
]}

Samson, Lindy ^{[6
,7
]}

Brophy, Jason ^{[6
,7
]}

机构：

[1] McGill Univ, Hlth Ctr, Chron Viral Illness Serv, Montreal, PQ, Canada

[2] Univ Hlth Network, Toronto Gen Hosp, Immunodeficiency Clin, Toronto, ON, Canada

[3] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada

[4] McGill Univ, Hlth Ctr, Quebec Antiretroviral Therapeut Drug Monitoring P, Montreal, PQ, Canada

[5] Univ Montreal, Fac Pharm, Montreal, PQ, Canada

[6] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada

[7] Univ Ottawa, Fac Med, Dept Pediat, Ottawa, ON, Canada

来源：

ANTIVIRAL THERAPY | 2017年 / 22卷 / 06期

关键词：

PHARMACOKINETICS; MOTHER;

D O I：

10.3851/IMP3139

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We report a case of therapeutic drug monitoring guided raltegravir use for the prevention of vertical HIV transmission in a premature neonate born to a woman living with perinatally acquired HIV and documented resistance to multiple HIV drugs. Maternal viral load was above 1,000 copies/ml at delivery. This case demonstrates delayed raltegravir elimination in a neonate born at 33 weeks gestational age and a need for less frequent raltegravir dosing than is used in older infants and children.

引用

页码：545 / 549

页数：5

共 14 条

[1] [Anonymous], 2013, PROD MON
[2] [Anonymous], 2014, P1097 RLAT PHARM SAF
[3] [Anonymous], 2015, PROD MON
[4] Badell ML, 2013, INFECT DIS OBSTET GY, V2013
[5] Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing
Clarke, Diana F.
Acosta, Edward P.
Rizk, Matthew L.
Bryson, Yvonne J.
Spector, Stephen A.
Mofenson, Lynne M.
Handelsman, Edward
Teppler, Hedy
Welebob, Carolee
Persaud, Deborah
Cababasay, Mae P.
Wang, JiaJia
Mirochnick, Mark
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 (03) : 310 - 315
[6] One-Month Transplacental Pharmacokinetics of Raltegravir in a Premature Newborn after Short-Course Treatment of the HIV-1-Infected Mother
Clavel-Osorio, C.
Cazassus, F.
Stegmann, S.
Huc-Anais, P.
Lecam, D.
Peytavin, G.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6393 - +
[7] Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population
de Vries-Sluijs, TEMS
Dieleman, JP
Arts, D
Huitema, ADR
Beijnen, JH
Schutten, M
van der Ende, ME
[J]. CLINICAL PHARMACOKINETICS, 2003, 42 (06) : 599 - 605
[8] Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates
Hegazi, Aseel
Mc Keown, Denise
Doerholt, Katja
Donaghy, Sheila
Sadiq, Syed T.
Hay, Phillip
[J]. AIDS, 2012, 26 (18) : 2421 - 2423
[9] THE PRENATAL AND POSTNATAL-DEVELOPMENT OF UDP-GLUCURONYLTRANSFERASE ACTIVITY TOWARDS BILIRUBIN AND THE EFFECT OF PREMATURE BIRTH ON THIS ACTIVITY IN THE HUMAN-LIVER
KAWADE, N
ONISHI, S
[J]. BIOCHEMICAL JOURNAL, 1981, 196 (01) : 257 - 260
[10] Krekels EHJ, 2012, CURR DRUG METAB, V13, P728

← 1 2 →